Physician profile
Jacob Smith
NPI 1265812796
$7,308.87
in general payments reported to CMS, 2019-2025
42 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $237 · 2021: $235 · 2022: $1,025 · 2023: $1,428 · 2024: $1,658 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,817.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.58 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $872.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $719.47 | 2019-2025 | |
| Novo Nordisk INC | $670.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $397.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.36 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $359.48 | 2019-2025 | Evenity, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $199.39 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $194.66 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $187.18 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $184.76 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $170.72 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $164.32 | 2024-2025 | |
| Exact Sciences Corporation | $163.94 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $158.45 | 2023-2025 | Dexcom G6 Transmitter |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.